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doi:10.1016/j.jtcvs.2007.01.087bjective: This study aimed to develop an autologous heart valve without using
raditional in vitro tissue-engineering methods, which necessitate complicated cell
anagement protocols under exceptionally clean laboratory facilities.
ethods: An autologous heart valve construct composed of trileaflets was prepared
sing a specially designed mold. The mold was prepared by covering a silicone rod with
crown-shaped tubular polyurethane scaffold containing 3 horns. The mold was
mplanted in the dorsal subcutaneous space in Japan White rabbits for 4 weeks. After
arvesting, the implanted trileaflet valve-shaped structure with an internal diameter of
ither 5 or 20 mm was obtained by trimming the membranous tissue formed between the
orns located around the silicone rod. The valve substitute was examined both macro-
copically and histologically. The tensile strength of the leaflets was measured to
upture. The degree of regurgitation in valve function was evaluated using a flow circuit
y calculating the ratio of the regurgitation volume to the forward flow volume.
esults: After implantation, the mold was completely covered with connective tissue
onsisting mostly of collagen and fibroblasts. Harvesting of the mold was straightfor-
ard, because there was little adhesion between the formed tissue and the native skin
issue. The trileaflet heart valve construct was obtained after withdrawing the inserted
ods and trimming the membranous tissues formed between the horns of the scaffold. It
as firmly attached to the scaffold, the interstices and surface of which revealed
onnective tissues composed of components similar to those of the leaflet tissue.
lthough the mechanical properties of the leaflet tissue were less efficient than those of
he native porcine aortic valve leaflets, satisfactory valvular functions were demon-
trated under pulsatile conditions using a flow circuit. No regurgitation was observed
nder retrograde hydrostatic pressures of up to 60 mm Hg, the physiologic pressure
cting on the aortic valves during retrograde aortic flow.
onclusions: The biovalve, an autologous, in vivo tissue-engineered, trileaflet,
alve-shaped construct, was developed using our novel in-body tissue architecture
echnology. The biovalve has the potential to be an ideal prosthetic heart valve, with
xcellent biocompatibility to the growth of the recipient’s heart.
rosthetic valve-replacement operations are currently regarded as the standard
treatment for end-stage heart valve diseases; however, several clinical prob-
lems resulting from the use of these artificial valves exist. Lifetime antico-
gulation therapy is necessary in the case of mechanical valves,1-4 whereas the
tructure of the xenogeneic valvular leaflets gradually deteriorates in the case of
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ETioprosthetic valves.5-7 Both types of prosthetic valves a
nsuitable for pediatric patients because of a lack of their
bility to grow.4 In recent developmental studies, to acqu
he characteristics of enhanced maturation, such as antico-
gulation, self-repair, tissue regeneration, and adaptability
o growth, autologous valve prostheses have been devel-
ped using in vitro tissue-engineering technology.8-11 Some
nvestigators have succeeded in the implantation of the in
itro tissue-engineered heart valves in animals and humans
sing scaffolds based on either decellularized natural tissues
r biodegradable synthetic polymers.11-21 However, it i
ifficult to fabricate reproducible valves with a certain level
f maturity.
For the development of autologous prosthetic tissues, we
ave embarked on a novel and practical concept in regen-
rative medicine, namely, in-body tissue architecture tech-
ology, which is based on the tissue-encapsulation phenom-
non of foreign materials in living bodies.22-24 The use of 
ecipient’s body to construct organ tissues was pioneered by
parks,25 who constructed arterial bypass grafts in rec-
nts’ subcutaneous spaces. In 1968, the silicone mandril
ethod was clinically applied to arterial bypass.26 Simi-
arly, Campbell and colleagues27,28 successfully constructed
rterial grafts in the peritoneal cavity of animals using
ilastic tubes. For in vivo cell seeding in bovine pericar-
ium, Flameng29 and De Visscher and colleagues30 also
sed foreign body reaction through intraperitoneal
mplantation.
This technique has the following advantages: The pros-
heses induce no immunologic rejection, exhibit nontoxic
iocompatibility, and may adapt to the recipient’s growth.
n addition, the tissue prostheses can be fabricated in a wide
ange of shapes and sizes to suit each individual recipient.
ost important, neither complex cell management in vitro
or exceptionally clean laboratory facilities are required,
oth of which are expensive and time-consuming.
The purpose of this study was to develop an autolo-
ous heart valve substitute using a more convenient and
ndemanding technique than the traditional in vitro tissue
ngineering technique. We describe a fabrication method
or the biovalve valvular structure by using a specially
esigned mold. The results of examining the mechanical
nd histologic properties of the biovalve are described.
e discuss the potential advantages and limitations of
he biovalve.
aterials and Methods
reparation and Characterization of the Biovalve
he molds were specially designed by covering a silicone rod with
crown-shaped tubular segmented polyurethane scaffold consist-
ng of 3 isosceles triangular horns with a microporous wall struc-
ure (internal diameter of the scaffold, 5 or 20 mm; wall thickness,
or 3 mm; micropore diameter, 50–100 m) fabricated by Bridge-tone Corp (Tokyo, Japan). A tapered silicone rod (diameter, 4 mm i
The Journal of Thoracictop] and 7 mm [bottom]; height, 15 mm), manufactured by Taiyo
ogyo Corp (Tokyo, Japan), was used for the 5-mm scaffold
Figure 1, A). In the case of the 20-mm scaffold, a cyli
ilicone rod (diameter, 20 mm; height, 45 mm) obtained from
aiyo Kogyo Corp was used. The mold was placed in the dorsal
ubcutaneous space of Japan White rabbits (n 4; average weight,
kg). All of the experimental animals received humane care
ccording to the “Principles of Laboratory Animal Care,” formu-
ated by the National Institutes of Health (National Institutes of
ealth publication no. 56-23, revised 1985). The research protocol
as approved by the ethics committee. Anesthesia was induced in
he rabbits by the intramuscular injection of a mixture of ketamine
62.5 mg/kg) and xylazine (8.3 mg/kg) and maintained by a bolus
ntramuscular injection of a quarter of the initial doses. After 4
eeks of placement, the implants were harvested. The biovalves
ere obtained from the implants after trimming the peripheral,
ragile, irregular redundant tissues; 3 notches were created on the
igid membranous tissues formed between the 3 horns of the
caffolds, and the molds were removed.
For histologic examination, the biovalves were fixed with 10%
uffered formalin solution, embedded in paraffin, cut into thin
ross-sections (thickness, 3-5 m), mounted, and stained with
ematoxylin-eosin and Sirius red. The biovalves were fixed with
0% buffered formalin solution, embedded in paraffin, cut into
ross-sections (thickness: 3-5 m), and mounted for histologic
hematoxylin-eosin and Elastica–van Gieson staining) studies.
mmunohistochemistry was performed using monoclonal antibod-
es against vimentin (DAKO Japan, Kyoto, Japan), -smooth
uscle antibody (DAKO Japan), and desmin (DAKO Japan). The
ections were treated with 0.3% H2O2 for 20 minutes to inhibit
ndogenous peroxidase activity and then incubated overnight with
he primary antibody (4oC). After the treatment with biotinylated
econdary antibodies, the sections were incubated with peroxidase-
onjugated streptavidin for 30 minutes. Finally, visualization was
erformed with 0.02% 3.3=-diaminobenzidine tetrahydrochloride
n 0.05 mol/L Tris-HCl buffer containing 0.005% H2O2 for 5
inutes.
hysical Properties of the Biovalve
easurements of the thickness and tensile strength of the biovalve
eaflets were performed using a tensile strength machine
RE-3305; Yamaden Co, Ltd, Tokyo, Japan). The specimens (size,
mm  10 mm) were stress-loaded to rupture at a rate of 0.5 mm
er second. The tensile strength denoted the amount of force
equired for rupture to occur. The apparent elastic modulus was
etermined as the slope of the initial linear section of the stress-
train curve.
Regurgitation of the biovalve was measured for a period of 1
inute under static pressure in a closed structure, 5 mm in size,
sing a specially designed flow-loading circuit that was capable of
enerating hydrostatic pressure by altering the revolutions of the
oller pump (pressure, 12–200 mm Hg). The degree of regurgita-
ion was estimated by the ratio of the regurgitation volume to the
orward flow volume.
esults
fter the specially designed molds (Figure 1, A) were placednto the subcutaneous pouches for 4 weeks, they became
and Cardiovascular Surgery ● Volume 134, Number 1 153
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ETompletely encapsulated with the newly developed mem-
ranous connective tissues (Figure 1, B). The implant
ould be easily harvested by cutting the surrounding tissues
ecause the newly developed connective tissues and the
riginal subcutaneous tissues were connected by fragile,
rregular, redundant tissues. Connective tissues were also
ormed in between the 3 horns of the crown-shaped 
old. The membranous tissues were thin and homogenous in
ature. After the inserted silicone rod was withdrawn, the
ubular connective tissue structure embedded within the
caffold was obtained. The biovalves were obtained after
utting the membranous tissue formed between the horns
nto the predesigned shape. By changing the size of the
old, 2 different types of the biovalves, with an internal
iameter of 5 or 20 mm, were obtained (Figure 1, C). The
arger biovalve may fit adult human aortic valves.
In longitudinal sections of the biovalve, it was observed
hat the luminal surface at the border between the leaflet
tructure and the scaffold was extremely smooth without
ny seam (Figure 2, A). Coaptation and opening of t
eaflets were well balanced (Figure 2, B, C). Histologic
nalysis confirmed that in circumferential sections, the leaf-
ets and polyurethane crowns were tightly connected to each
ther and unified with the same newly formed connective
issues (Figure 3, A, C). The thickness of the leaflets w
pproximately 200 m. Rich angiogenesis was induced
ear the scaffold (Figure 3, B).
Elastica–van Gieson staining revealed the absence of
lastic fibers in the membranous leaflet tissue; however,
ich collagen fibers were present (Figure 4, A ). Immuno-
istochemistry revealed that fibroblasts and myofibro-
lasts were the most predominant cell types in the leaflet
issues. Smooth muscle cells were not observed (Fig
, B, C, D).
The mechanical properties of the prepared leaflet tis-
ues were evaluated by estimating their tensile strength.
he load-deformation relationships obtained by causing
xpansion of the leaflets were compared among the two
ifferent sizes of the biovalves and porcine aortic valves
f 20 mm in diameter (radial and circumferential direc-
ions) (Figure 5). The relation curve of leaflets from
0-mm biovalves was equivalent to that of the porcine
ortic valves in the radial direction. Table 1 summa
he mechanical properties of the leaflets. The thickness of
he 20-mm biovalve leaflets was 3 times that of the 5-mm
iovalves; this difference was reflected in their respective
echanical properties. The 20-mm biovalve leaflets en-
ured more than 150% deformation. Both tensile strength
nd elastic modulus values of the 20-mm biovalves were
quivalent to those of the porcine leaflets in the radial
irection; however, these values were approximately half
f those of the porcine leaflets in the circumferential v
54 The Journal of Thoracic and Cardiovascular Surgery ● July-
irection. Nevertheless, these values were twice as much
s those of the 5-mm biovalves.
The 5-mm biovalves exhibited excellent performance in
erms of tight closure during the diastolic phase and quick
pening during the systolic phase. No major regurgitation
as observed under retrograde static pressures of up to 60
m Hg (retro/ante ratio  0) during pulsatile flow condi-
ions (Figure 6). Even at a pressure of more than
m Hg, the ratio of the regurgitation volume to the forward
ow volume of the circuit was approximately 0.1.
iscussion
ur goal in creating maximally effective heart valve
rostheses is to ensure their biocompatibility, satisfactory
alvular function, and lifelong adaptability to the recip-
ents’ bodies. To acquire biocompatibility, autologous
ell-incorporated heart valves have been developed with
he help of the recent advances in in vitro tissue-engi-
eering techniques. Some investigators have successfully
mplanted valve substitutes during animal experiments
nd in the clinical setting20,31-33; autologous bone ma-
ow cells and vascular-composing cells, both of which
ere carefully harvested from the recipients’ bodies,
ere used as cell sources in these instances. However,
hese procedures require complicated cell-management
rotocols, including cell harvesting, seeding of the cells
o appropriate scaffolds, and culturing of the cells for the
evelopment of neotissues in bioreactors under strictly
terile conditions; all of these procedures require enor-
ous amounts of time and money. When a homograft or
enograft instead of polymeric materials is used as the
caffold, complete decellularization is indispensable to
xclude all immunologic sources to avoid subsequent
alcification.11 These complex procedures could lim
heir safety, dependability, and popularity in the future.
issue-engineered valves are now used only in the cases
f pulmonary position under low pressures of up to 40 to
0 mm Hg because after culture and development in a
ioreactor, they are not matured enough to sustain the
igh pressure of the arterial circulation systems.16-21
In comparison, the in-body tissue architecture technol-
gy, which we have described above, used a living body
s a “reactor” to fabricate valvular tissues. While fabri-
ating the autologous implants with this technique, we
sed and controlled the extracellular matrix components
roduced by the body’s own fibroblasts or myofibroblasts
hat exist abundantly in subcutaneous tissues.24,32-36
herefore, the preparation method of the biovalves was
traightforward, safe, and reproducible. Only 2 processes
ere necessary, namely, embedding a synthetic scaffold
nto the recipients’ subcutaneous spaces and harvesting
nd trimming the regenerated tissues. Because the bio-
alves were produced autonomically in the recipients’
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ETodies, neither complicated cell-management methods
or development of neotissues in vitro was essential. In
ddition, the risks of bacterial contamination and trans-
ission of infection to the recipients are considered less
n this technique.
In this study, a microporous polyurethane tube cut into a
imple crown shape was prepared as a scaffold. Polyure-
igure 1. A, Gross appearance of the assembly consisting of a
rown-shaped scaffold made of polyurethane and a silicone rod
old. The latter was inserted into the former. Scale bar: 5 mm. B,
he biovalve organized in subcutaneous spaces of rabbits for 4
eeks before trimming. The surface was completely encapsu-
ated by connective tissues with rich neovascularization. Little
dhesion to the surrounding native tissues enabled easy harvest-
ng. Scale bar: 5 mm. C, The biovalves completed by trimming of
he redundant membranous tissues formed between the 3 notches
n the crown-shaped scaffold.hanes, which are clinically used in blood pumps and arterial T
The Journal of Thoracicrafts, exhibited no toxicity and little biodegradation in
ivo.37,38 With regard to the use of the polyurethane,
ave demonstrated its good biocompatibility in a discrete
eries of experiments using dogs and rabbits. In these ex-
eriments, no anomalous accumulation of inflammatory
ells around the scaffolds was observed during the fourth
eek; this observation was also demonstrated in this study
Figure 3). In addition, rapid and homogenous tissue 
ration was observed in the deep layer of the scaffolds. In
he next stage of our research, we are planning the use of
iodegradable scaffold materials so that attainment of
roper adaptability for the growth of the tissue is possible.
igure 2. Macroscopic observation of the biovalve. A, Longitudi-
al section of the boundary between the polyurethane scaffold
nd the leaflet tissues. Closed form (B) and open form (C) of the
iovalve observed from the bottom. Well-balanced coaptation
nd sufficient opening of the leaflets were observed. Scale bar:
mm.o form membranous tissues as leaflet parts between the
and Cardiovascular Surgery ● Volume 134, Number 1 155
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1
ETorns of the scaffolds, silicone rods were inserted into the
caffolds in this study. Because the encapsulating tissues did
ot adhere to the silicone molds, the biovalve leaflets could
e easily obtained by extracting the rods and trimming away
he redundant tissues.
In the histologic examinations, the extracellular matrix of
he biovalve leaflets was observed to be mainly composed
f collagen fibers (Figures 3 and 4, A ) . W e could n
xactly reproduce the same components of the native aortic56 The Journal of Thoracic and Cardiovascular Surgery ● Julyalves, such as elastin, which is one of the major extracel-
ular matrix proteins. However, it is presumed that matura-
ion into highly differentiated tissues, including those dem-
nstrating elastic fiber formation, could be induced under
he mechanical stresses of pulsatile blood pressure and the
pening and closing movements after implantation in the
emodynamic conditions in vivo. Indeed, in our implanta-
ion study on small-caliber tubular prostheses known as
iotubes, which were developed by the application of the
Figure 3. Histologic images of the cir-
cumferential whole (A) and part (C)
sections obtained from the biovalve.
The membranous leaflet tissues were
firmly attached to the tissue growing
into the interstices of the scaffold. The
leaflets mainly consisted of fibroblasts
and collagen-rich extracellular matri-
ces (D). B, Histologic image of a poly-
urethane scaffold of the Biotubes. The
micropores of the scaffold were fully
occupied by connective tissue with
rich neovascularization (arrows). Few
inflammatory cells were observed.
Histologic staining: hematoxylin-eosin
stain (A, B, C); Sirius red stain (D).
Scale bar: A, 1 mm; B, 50 m; C, 200
m; D, 200 m.
Figure 4. Elastica–van Gieson staining
(A) of the membranous tissue of the
biovalve leaflets showed the presence
of collagen fibers. The cellular compo-
nents showed immunoreactivity for
-smooth muscle actin (B) and vimen-
tin (C); however, the cells were nega-
tive for desmin (D). Scale bars: 50 m.2007
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ETn-body tissue architecture technology, hierarchic vascular
tructure formation, including the regeneration of elastic
bers, was observed 3 months after implantation.36
Another structural difference between the biovalves and
he native valves was that their blood-contacting surface
as thrombogenic in nature. However, on implantation
n vivo, natural antithrombogenecity could be obtained
apidly, as discussed below. In animal experiments using
iotubes coated with nonthrombogenic agents, such as
rgatroban, graft patency was excellent and complete endo-
helialization was induced within 2 weeks.30 Therefore,
mplanted Bivalves are also expected to be completely
overed with endothelial cells forthwith. We could control
igure 5. The load-deformation relationships, obtained by caus-
ng expansion of the leaflets, compare the 2 different sizes of
iovalves and porcine aortic valves of 20 mm in diameter (radial
nd circumferential directions). The relation curve of leaflets
rom the 20-mm biovalves was equivalent to that of the porcine
ortic valves in the radial direction.
ABLE 1. Physical properties of the biovalve leaflets
Thickness m Tensile strength g
iovalve
5 mm (n  30) 197.5  60.4 307.8 66.5*†
20 mm (n  42) 667.1  100.6 802.5 202.2*
orcine aortic valve
Circumferential (n  6) 409.4  252.4 1475.0 367.9
Radial (n  6) 484.4 125.1 824.8 411.2
ll values are mean  standard deviation. *P  .05 versus porcine aortic
irection. The specimens from biovalves were sampled from 4 rabbits.
The Journal of Thoraciche strength and thickness of the regenerated membranous
issues to a certain degree by changing the size of the molds
Table 1). When we used a lager mold, the thickness 
embranous tissues increased and the tissues became
tronger.
In regurgitation tests, the biovalves showed high resis-
ance to retrograde pressure (Figure 6). Even the 5
iovalves endured 100 to 200 mm Hg hydrostatic pressures.
ecause the 20-mm biovalves demonstrated better mechan-
cal properties in strength or extensibility than the 5-mm
iovalves, we suggested that they also could sustain the high
ressure extant in the arterial system.
We created functional prototype models of autologous
eart valvular tissues in subcutaneous spaces. The biovalves
igure 6. Regurgitation test under static pressure against a
losed biovalve of 5-mm size using a flow loading circuit. No
ajor regurgitation was observed under physiologic diastolic
lood pressure.
Elongation at maximum stress, % Apparent elastic modulus, gf/mm
43.1 5.4† 251.9  90.6*
53.7 8.4 415.4  58.8*
68.0 35.3 837.5  220.9
65.0 13.5 410.4  196.9
of circumferential direction. †P  .05 versus porcine aortic valve of radialf
valveand Cardiovascular Surgery ● Volume 134, Number 1 157
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1
ETave already achieved satisfactory levels in terms of me-
hanical properties and valvular functions.
One of our challenges in the development of the
iovalves is to improve the design of the mold and
caffold to achieve more functional and biomimetic
tructures with the sinus of Valsalva. Moreover, we need
o demonstrate the possibility of regeneration and tissue
estoration, influence of physical stresses on valvular
issue formation, and adaptability to size discrepancy in
ivo, especially in the arterial system. We intend to
ddress these issues through animal implantation exper-
ments. Subsequently, long-term function and tissue re-
rganization will be investigated in follow-up studies, in
ddition to the evaluation of surgical safety and the
rimary function of the biovalves.
onclusions
wo sizes of in vivo tissue-engineered, autologous, trileaf-
et, valve-shaped biovalves were successfully produced by
n-body tissue architecture technology. This new type of
io-added valve prosthesis was, on the whole, satisfactory
n terms of valvular functions and mechanical properties.
herefore, biovalves have the potential to be ideal prosthetic
eart valves with high biocompatibility to the growth of the
ecipient’s organ.
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